Why Is Rein Therapeutics Stock Trading Higher On Monday?

RNTX stock rose 16.29% amid high trading volume. FDA lifted clinical hold on LTI-03 RENEW trial. Patient recruitment for the trial expected to restart by 2026. LTI-03 aims to treat idiopathic pulmonary fibrosis. Topline data from the trial anticipated in late 2026.

US FDA puts on hold Rein Therapeutics' lung disease drug trial

RNTX paused mid-stage trial due to FDA clinical hold. This could delay drug development and impacts investor confidence.

RNTX

RNTX price chart

Why Is Rein Therapeutics Stock Trading Higher On Monday?

US FDA puts on hold Rein Therapeutics' lung disease drug trial

Company intelligence